Recently, BeiGene Ltd’s lymphoma treatment Brukinsa was approved by the U.S. Food and Drug Administration. This is the first time a drug developed predominantly in China by a Chinese biopharma sponsor has been approved within America. The key clinical trials...
BeiGene Ltd’s lymphoma treatment was recently approved by the U.S. Food and Drug Administration. This is the first time a company developed predominantly in China has been approved within America. Brukinsa was studied in 118 patients with mantle cell lymphoma...
A Phase I clinical trial, which has focused on patients with chronic lymphocytic leukemia (CLL) and a half dozen patients with mantle cell lymphoma (MCL), will now expand to include more MCL patients. The study combines an antibody discovered at University of...
An MD Anderson-developed drug looks to be effective in overcoming ibrutinib resistance in mantle cell lymphoma. The University of Texas, MD Anderson Cancer Center led a study demonstrating how a small molecule drug discovered at the institution may help overcome...
The recent phase 2 CALGB 50403 clinical trial reveals that treatment with either consolidation therapy (to kill any cancer cells that may be let in the body), or maintenance therapy (to help keep cancer from coming back) with Takeda’s Velcade (bortezomib), following...
Targeted Oncology’s Jason Harris, Mutations of TP53 and WHSC1 predicted poorer overall survival (OS) in patients with mantle cell lymphoma (MCL), according to results from next-generation whole-exome sequencing of 16 Chinese patients.1 The presence of these mutations...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
